Minjuvi Or Monjuvi Market Report 2026

Minjuvi Or Monjuvi Market Overview

• The Minjuvi Or Monjuvi market growth in the historic period has been driven by increasing incidence of diffuse large b-cell lymphoma, rising adoption of biologic cancer therapies • Market expansion is supported by increasing demand for personalized cancer treatments, rising investments in oncology biologics research • Growth Driver: Increase In Cancer Prevalence Driving Growth Of The Market • Market Trend: Innovation In Combination Therapy For Relapsed Or Refractory Diffuse Large B-cell Lymphoma (DLBCL) • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Minjuvi Or Monjuvi Market?

Minjuvi (tafasitamab) is a monoclonal antibody used to treat relapsed or refractory diffuse large B-cell lymphoma (DLBCL) by targeting and binding to CD19 on malignant B cells, which triggers immune system-mediated destruction through antibody-dependent cellular cytotoxicity (ADCC) and apoptosis. This mechanism helps reduce tumor burden by eliminating cancerous B cells while sparing normal ones. The main indication types of minjuvi or monjuvi are relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and others. Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) refers to cases where the lymphoma returns after treatment or does not respond to the initial therapy. The formulations are intravenous infusions and pre-filled syringes, and the distribution channels include hospitals, oncology clinics, specialty pharmacies, and home healthcare services. It is used by various end-user patients, such as adult patients and geriatric patients.

What Is The Minjuvi Or Monjuvi Market Growth Forecast?

The growth in the forecast period can be attributed to increasing demand for personalized cancer treatments, rising investments in oncology biologics research, expansion of combination therapy approvals, growing focus on outpatient oncology care, increasing adoption of targeted immunotherapies. Major trends in the forecast period include increasing adoption of targeted monoclonal antibody therapies, rising use of combination regimens in lymphoma treatment, growing focus on precision oncology approaches, expansion of cd19-directed therapeutic applications, enhanced emphasis on improved patient outcomes.

Global Minjuvi Or Monjuvi Market Segmentation

1) By Indication: Relapsed Or Refractory Diffuse Large B-cell Lymphoma (DLBCL), Other B-Cell Malignancies 2) By Formulation: Intravenous Infusion, Pre-Filled Syringes 3) By Distribution Channel: Hospitals, Oncology Clinics, Specialty Pharmacies, Home Healthcare Services 4) By End User Patients: Adult Patients, Geriatric Patients

What Is The Driver Of The Minjuvi Or Monjuvi Market?

The increase in the prevalence of cancer is expected to propel the growth of the minjuvi or monjuvi market going forward. Cancer is a group of diseases characterized by the uncontrolled growth and spread of abnormal cells in the body. The prevalence of cancer is attributed to aging, lifestyle factors such as smoking and poor diet, environmental exposures, genetic factors, and improved detection methods. Minjuvi (Monjuvi), in combination with lenalidomide, is used to treat relapsed or refractory diffuse large B-cell lymphoma (DLBCL), enhancing treatment options by targeting cancer cells effectively. For instance, in August 2024, according to a report published by the Australian Institute of Health and Welfare, an Australian-based national agency for information and statistics on Australia's health and welfare, by 2034, Australia is projected to have approximately 209,000 new cancer diagnoses, a significant increase from the estimated 169,000 cases expected in 2024. Additionally, in 2024, cancer is anticipated to account for about 3 out of every 10 deaths in the country. Therefore, the increase in the prevalence of cancer is driving the growth of the minjuvi or monjuvi industry.

Key Players In The Global Minjuvi Or Monjuvi Market

Major companies operating in the minjuvi or monjuvi market are Incyte Corporation

Global Minjuvi Or Monjuvi Market Trends and Insights

A key trend in the minjuvi or monjuvi market is the development of innovative therapies, such as combination therapy, to improve treatment efficacy and outcomes for patients with B-cell malignancies, particularly relapsed or refractory DLBCL. Combination therapy is using two or more treatments, such as medications or therapies, together to treat a medical condition. This approach aims to enhance the overall effectiveness of treatment, often by targeting different pathways or mechanisms involved in the disease. For instance, in February 2024, Knight Therapeutics Inc., a Canada-based pharmaceutical company, launched Minjuvi (tafasitamab) by its Brazilian affiliate, United Medical Ltda. In combination with lenalidomide, Minjuvi (tafasitamab) is an immunotherapy treatment for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) patients who are ineligible for autologous stem cell transplantation. The combination has shown a significant objective response rate and is a preferred second-line treatment according to NCCN guidelines.

What Are Latest Mergers And Acquisitions In The Minjuvi Or Monjuvi Market?

In February 2024, Incyte Corporation, a US-based pharmaceutical company, acquired full rights to monjuvi from morphoSys AG for $25 million. The acquisition aims to provide Incyte with full control over Monjuvi's global commercialization and clinical development, enhancing operational efficiencies and driving cost synergies. This strategic move allows Incyte to capitalize on the drug's potential to expand lymphoma treatment indications. MorphoSys AG is a Germany-based biotech company that specializes in providing monjuvi.

Regional Insights

North America was the largest region in the minjuvi or monjuvi market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Minjuvi Or Monjuvi Market?

The minjuvi or monjuvi market consists of sales of monoclonal antibody therapies, combination therapies, and biosimilars. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Minjuvi Or Monjuvi Market Report 2026?

The minjuvi or monjuvi market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the minjuvi or monjuvi industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.